Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Total Non-Current Liabilities (2017 - 2024)

Historic Total Non-Current Liabilities for Utah Medical Products (UTMD) over the last 12 years, with Q4 2024 value amounting to $5.1 million.

  • Utah Medical Products' Total Non-Current Liabilities fell 2072.28% to $5.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.1 million, marking a year-over-year decrease of 2072.28%. This contributed to the annual value of $5.1 million for FY2024, which is 2072.28% down from last year.
  • Utah Medical Products' Total Non-Current Liabilities amounted to $5.1 million in Q4 2024, which was down 2072.28% from $4.8 million recorded in Q3 2024.
  • Over the past 5 years, Utah Medical Products' Total Non-Current Liabilities peaked at $8.7 million during Q1 2022, and registered a low of $4.8 million during Q3 2024.
  • In the last 5 years, Utah Medical Products' Total Non-Current Liabilities had a median value of $7.0 million in 2020 and averaged $7.0 million.
  • As far as peak fluctuations go, Utah Medical Products' Total Non-Current Liabilities tumbled by 3448.94% in 2020, and later soared by 2402.42% in 2021.
  • Utah Medical Products' Total Non-Current Liabilities (Quarter) stood at $6.9 million in 2020, then fell by 1.52% to $6.8 million in 2021, then grew by 22.59% to $8.4 million in 2022, then fell by 22.92% to $6.4 million in 2023, then dropped by 20.72% to $5.1 million in 2024.
  • Its Total Non-Current Liabilities stands at $5.1 million for Q4 2024, versus $4.8 million for Q3 2024 and $5.3 million for Q2 2024.